Global Carrier Screening Market to Grow at a CAGR of 12.4% During 2024-2032, Driven by Increasing Awareness of Genetic Disorders

The carrier screening market size is driven by increasing awareness of genetic disorders, advancements in genetic testing technologies, and the growing demand for early detection and preventive care. Rising adoption of next-generation sequencing (NGS) and expanded carrier screening panels enhance diagnostic accuracy, while supportive government initiatives and reimbursement policies further fuel market growth.

In January 2023 , MedGenome, a leading genetic diagnostic firm, announced plans to consider inorganic growth to target emerging markets. With over 1,300 tests in its portfolio, the company aims to expand its reach through strategic partnerships. Using artificial intelligence and machine learning, MedGenome covers areas like inherited diseases, reproductive health, cancer, infectious diseases, and consumer wellness. They are evaluating targets for their Claria and Prima segments, focusing on mergers and acquisitions.

Claria offers a suite of highly accurate tests, including the Non-Invasive Prenatal Screening Test (NIPT), Genetic Carrier Screening Test (GCST), and Preimplantation Genetic Screening/Diagnosis (PGS/PGD). MedGenome also collaborates with pharma companies for precision medicine programs. Recently, they acquired Trident Diagnostics to expand in tier 2 and tier 3 cities, aiming to increase the accessibility and affordability of genetic tests.

In February 2023 , Fulgent Genetics, Inc. launched its new Beacon787 expanded carrier screening panel, featuring 787 genes associated with autosomal recessive and X-linked conditions. This panel, the largest available on Fulgent's platform, includes all of the American College of Medical Genetics and Genomics (ACMG) tier 3 genes, recommended for equitable, pan-ethnic carrier screening for pregnant patients and those planning pregnancy.

Leveraging its proprietary platform, Fulgent offers rapid turnaround times and high analytical detection rates. Fulgent's optimized workflow for variants with pseudogene interference ensures accurate testing, distinguishing positive and negative cases efficiently. Carrier screening is crucial for individuals and couples considering pregnancy, providing insights for informed family planning decisions.

The market is experiencing robust carrier screening market growth driven by increasing awareness about genetic disorders and the availability of advanced screening technologies. Carrier screening plays a critical role in identifying individuals at risk of passing genetic disorders to their offspring, making it a key component of family planning and prenatal care. With the rise in genetic testing options and the expansion of screening panels, more individuals and couples are opting for carrier screening to assess their genetic risks before conceiving.

One of the major drivers of demand in the carrier screening market is the growing emphasis on personalized medicine and precision healthcare. Healthcare providers are increasingly recognizing the value of genetic information in tailoring treatments and preventive measures for individuals. This has led to a surge in demand for comprehensive carrier screening tests that can provide detailed insights into an individual's genetic makeup and potential risks.

Moreover, the increasing adoption of carrier screening by healthcare providers and laboratories globally is driving carrier screening market demand. The availability of advanced technologies, such as next-generation sequencing (NGS) and improved bioinformatics algorithms, has made carrier screening more accurate, efficient, and cost-effective. This has encouraged more healthcare providers to offer carrier screening as part of their routine care, further boosting market growth.

The market is witnessing significant demand driven by heightened awareness, expanding screening panels, personalized medicine trends, and improved screening technologies. As genetic testing continues to advance, the carrier screening market is expected to expand further, providing individuals and couples with valuable genetic information for informed family planning decisions.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Analysis by Type, Product and Service, Technology, Medical Conditions, End Users, and Region

• By type, the market includes expanded carrier screening, targeted disease carrier screening, customized panel testing, and predesigned panel testing, offering different approaches to genetic screening based on individual needs and preferences.

• The market is segmented by product and service, comprising products and services offered in carrier screening.

• In terms of technology, the carrier screening market segmentation constitutes various methodologies such as DNA sequencing, polymerase chain reaction (PCR), microarrays, and others, each offering specific advantages in terms of accuracy, output, and cost-effectiveness.

• Medical conditions targeted in carrier screening include hematologic conditions, pulmonary conditions, neurological conditions, and others, addressing a broad spectrum of genetic disorders.

• End-users of carrier screening services and products include hospitals and clinics, laboratories, fertility clinics, and other healthcare facilities, catering to diverse patient populations and clinical settings.

• Geographically, the market report offers insights on North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa, with each region contributing to the overall growth of the carrier screening market through factors such as healthcare infrastructure, regulatory landscape, and technological advancements.

Key Findings of the Report

• The report highlights a significant rise in the prevalence of genetic disorders worldwide. Factors such as consanguineous marriages, advanced maternal age, and increased awareness of genetic testing contribute to the expanding demand for carrier screening tests.

• The carrier screening market analysis emphasizes the continuous advancements in genetic testing technologies, leading to improved accuracy, sensitivity, and cost-effectiveness of carrier screening tests. Innovations such as next-generation sequencing (NGS) and microarray-based techniques enhance the detection capabilities for carriers of genetic mutations.

• Carrier screening is increasingly being integrated into prenatal and preconception care protocols, fostering early identification of genetic risks in couples planning for pregnancy. This trend reflects a shift towards proactive genetic counseling and personalized reproductive decision-making, thereby driving market growth.

• There is a notable trend towards the adoption of expanded carrier screening panels, offering a comprehensive analysis of numerous genetic mutations associated with a wide range of inherited conditions. This broader approach provides healthcare providers and individuals with more comprehensive insights into potential genetic risks, thereby fueling market expansion.

• The report offers insights into the development and implementation of ethnic-specific carrier screening programs tailored to diverse populations. Recognizing the significant genetic variability across different ethnic groups, healthcare providers are increasingly offering targeted screening panels designed to address the unique genetic profiles and risks prevalent within specific demographics. This targeted approach is poised to drive market growth by enhancing the relevance and effectiveness of carrier screening initiatives.

Key Offerings of the Report

• The EMR report gives an overview of the global carrier screening market for the periods (2017-2023) and (2024-2032).

• The report also offers the historical (2017-2023) and forecast (2024-2032) market insights for the type, product and service, technology, medical conditions, end users, and regions.

• The report analyses the market dynamics, covering the key demand and price indicators in the market, along with an assessment of the SWOT and Porter’s Five Forces models.

The major players in the global carrier screening market are Thermo Fisher Scientific, Invitae Corporation, Fulgent Genetics, Otogenetics, OPKO Health Inc., Quest Diagnostics Clinical Laboratories, Inc., Myriad Genetics, Inc., Natera, Inc., Laboratory Corporation of America® Holdings, Illumina, Inc., MedGenome, and CENTOGENE N.V.

Key Highlights of the Report

About Us:

Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.

EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over a 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.

Contact Us:

Expert Market Research
Website: www.expertmarketresearch.com
Email: [email protected]
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.